DEFA14A: Cosmos Health Unveils $300M Digital Treasury, US Expansion

Cosmos Health Inc. details its strategic vision, financial performance, and future growth initiatives, including a $300 million digital asset facility and U.S. manufacturing expansion.

Summary

• The Chief Executive Officer's annual letter to shareholders for the year ended December 31, 2024, dated September 29, 2025, was made available.
• Secured a $300 million senior secured convertible promissory note financing facility in August 2025 from a U.S. institutional investor.
• 72.5% of net proceeds from the facility will be directed toward building a digital treasury reserve, including Ethereum (ETH), Bitcoin (BTC), and Solana (SOL), with capacity to invest over $200 million in digital assets.
• The remaining proceeds from the facility will be allocated to working capital and accelerating growth initiatives, both organic and through acquisitions.
• Expanded manufacturing capabilities through Cana Laboratories in Athens, Greece, completing Phase I upgrades in 2024, with investments expected to generate over $10 million in recurring annual gross profit at full capacity.
• Cana Laboratories secured long-term contract manufacturing agreements, including a 5-year agreement for 1.5 million bottles of Ambitasol 1L with Pharmex, and a 10-year contract for 8 million packs across four products with Provident Pharmaceuticals.
• Established U.S.-based GMP-certified production in 2025 through a partnership with NOOR Collagen, projected to generate over $12 million in annualized revenue at approximately 75% gross margins.
• Sky Premium Life, the flagship nutraceutical brand, expanded its portfolio to over 150 premium products in 2025 and launched U.S. operations, along with distribution agreements in UAE, Oman, Qatar, Central Europe, Cyprus, Malta, and Albania.
• CosmoFarm, the wholesale and logistics arm, achieved record revenue of approximately $43 million in the first ten months of 2024, an 8.62% increase over 2023, with gross profit rising by 21%, and is projected to surpass $50 million in annualized revenue.
• Advanced proprietary obesity treatment, CCX0722, beyond laboratory development into the clinical trial preparation stage, with a potential launch as early as 2026.
• Expanded R&D pipeline and intellectual property across multiple therapeutic areas, including oncology, autoimmune, and neurological disorders, leveraging the AI-enabled drug repurposing platform, Cloudscreen.
• Acquired a 10-drug generics portfolio in 2024, providing direct exposure to the global generics market.
• The CEO, Greg Siokas, has invested over $18 million of personal capital into the Company and holds over 6 million shares, demonstrating strong insider commitment.
• 2024 revenues increased to $54.43 million, an approximately 2% gain over 2023, while operating expenses decreased by approximately 24% year over year.
• 2024 Adjusted EBITDA was ($3.73 million), compared to a small gain in 2023, and net loss widened to ($4.74 million), primarily due to increased investments.
• H1 2025 revenue reached $28.46 million, an 11.7% increase compared to $25.49 million in H1 2024, with gross profit rising to $3.21 million, up 53% year over year.
• As of June 30, 2025, total assets were $61.84 million (up 13.9% from year-end 2024), and stockholders' equity was $26.23 million (up from year-end 2024).
• Targeting approximately $155.8 million in revenue and $29.4 million in Adjusted EBITDA by 2027, with positive operating cash flow as a central near-term milestone.
• Evaluating strategic options such as a potential spin-off of the R&D division to unlock further value.

Sentiment

Score: 8

Explanation: The filing presents a highly optimistic outlook, emphasizing significant strategic achievements like the $300 million digital asset facility, global manufacturing expansion, strong brand growth, and substantial R&D progress. While 2024 saw negative EBITDA and net loss, these are framed as necessary investments leading to accelerated positive momentum in H1 2025 and ambitious 2027 targets. The CEO's substantial personal investment further reinforces confidence.

Positives

• Secured a substantial $300 million digital asset financing facility, providing significant capital for growth and diversification.
• Achieved significant expansion of manufacturing capabilities with Phase I upgrades at Cana Laboratories completed and new U.S.-based GMP-certified production established.
• Cana Laboratories secured multiple long-term contract manufacturing agreements, providing stable revenue streams and visibility.
• Sky Premium Life, the flagship nutraceutical brand, demonstrated strong global expansion and product portfolio growth, entering new key markets.
• CosmoFarm wholesale business delivered record revenue growth (8.62% increase in 10M 2024) and strong gross profit growth (21%), projected to surpass $50 million in annualized revenue.
• Advanced proprietary obesity treatment (CCX0722) to clinical trial preparation, indicating progress in a high-potential market.
• Demonstrated strong R&D and intellectual property expansion, leveraging AI (Cloudscreen) for accelerated drug discovery and new patent filings.
• Diversified the product portfolio with the acquisition of a 10-drug generics portfolio and expansion into diagnostics and hygiene brands.
• The CEO's significant personal investment of over $18 million and holding over 6 million shares signals strong insider conviction and alignment with shareholder interests.
• H1 2025 showed accelerated positive momentum with 11.7% revenue growth and a substantial 53% increase in gross profit year-over-year.
• Improved balance sheet strength in H1 2025, with total assets increasing by 13.9% and stockholders' equity improving.
• Implemented meaningful cost-cutting measures in 2024, resulting in a 24% decrease in operating expenses.
• Provided clear and ambitious financial targets for 2027, including significant revenue and adjusted EBITDA growth, and the achievement of positive operating cash flow.

Negatives

• 2024 Adjusted EBITDA was negative ($3.73 million), a decline from a small gain in 2023.
• 2024 Net loss widened to ($4.74 million).
• Increased investments in facilities and research and development contributed to the negative adjusted EBITDA in 2024.

Risks

• The Company's ability to raise sufficient financing to implement its business plan.
• The effectiveness of its digital asset strategies, including accumulation and yield-generating activities.
• The impact of the war in Ukraine on the Company's business, operations, and the economy in general.
• The Company's ability to successfully develop and commercialize its proprietary products and technologies.
• Actual results may differ significantly from the results discussed in forward-looking statements.
• Market volatility, which could impact shareholder value.

Future Outlook

Cosmos Health is targeting continued growth and profitability, aiming for approximately $155.8 million in revenue and $29.4 million in Adjusted EBITDA by 2027, with a central near-term milestone of achieving positive operating cash flow. This trajectory will be driven by scaling branded products, expanding utilization at Cana Laboratories and U.S. facilities, enhancing CosmoFarm's efficiency and reach, and maintaining strict financial discipline. The company plans to expand its global reach across Europe, North America, the Middle East, and Asia, scale branded nutraceuticals and pharmaceuticals, build a proprietary therapeutics pipeline, and leverage AI and blockchain to redefine drug discovery and corporate treasury management. The company is also evaluating a potential spin-off of its R&D division.

Management Comments

• "Cosmos Health stands at a defining moment in its journey. Over the past year, we have made decisive progress refining our strategy, reinforcing our operations, and positioning every business unit to contribute to a common vision of sustainable growth and long-term value creation."
• "Looking ahead to 2030, our ambition is to transform Cosmos Health into a global powerhouse."
• "The Company doesn't view digital-asset treasury reserve as a speculative side venture; it is central to our broader vision."
• "As both CEO and a long-term shareholder, I want to emphasize my personal commitment. Since the inception of Cosmos Health, I have invested more than $18 million of my own capital into the Company, and I now hold over 6 million shares."
• "With your trust and support, I am confident that the momentum we are building today will translate into lasting value and enduring success in the years to come."

Industry Context

Cosmos Health is positioning itself as a diversified, vertically integrated global healthcare group, aligning with broader industry trends of consolidation, digital transformation (AI, blockchain, digital treasury), and global market expansion in pharmaceuticals, nutraceuticals, and diagnostics. The focus on AI-driven drug discovery (Cloudscreen) and digital asset integration for treasury management reflects a forward-looking approach to healthcare and finance, aiming to differentiate in a competitive landscape. The expansion into U.S. manufacturing addresses supply chain resilience and market access, while the emphasis on natural product formulations and patient access aligns with growing consumer demand for wellness and accessible healthcare solutions.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or global benchmarks.
• The company aims to build a "proprietary therapeutics pipeline with multi-billion-dollar market potential," which is a common ambition in the pharmaceutical R&D sector.
• The digital asset treasury reserve, with capacity to invest over $200 million, is highlighted as creating "one of the largest corporate digital treasury reserves," suggesting a unique or leading position in this specific financial strategy for a healthcare company.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic growth, financial innovation (digital treasury), and targeted profitability by 2027. The CEO's significant insider purchases align management interests with shareholders.
• Employees: Expansion of manufacturing and R&D activities may lead to job creation and opportunities within the company.
• Customers: Increased access to high-quality healthcare products (nutraceuticals, pharmaceuticals, diagnostics, hygiene) globally, with a focus on innovation and patient well-being.
• Suppliers: Potential for increased demand for raw materials and services due to manufacturing expansion and product diversification.
• Creditors: The $300 million financing facility and bond loan represent new liabilities, but the company emphasizes a prudent capital structure and strengthening balance sheet, aiming to maintain financial discipline.

Next Steps

• Maximize the impact of the $300 million digital asset facility through disciplined treasury management and channeling resources into core healthcare businesses.
• Further expand output at Cana Laboratories through Phase II upgrades.
• Continue R&D for additional Sky Premium Life formulations for 2026.
• Advance CCX0722 proprietary obesity treatment into clinical evaluation, with a potential launch as early as 2026.
• Expand R&D pipeline and intellectual property across multiple therapeutic areas, leveraging Cloudscreen.
• Actively pursue a potential supply contract with the UK National Health Service (NHS) for C-Sept and C-Scrub hygiene brands.
• Achieve positive operating cash flow as a central near-term milestone.
• Scale branded product portfolio, particularly Sky Premium Life and proprietary pharmaceuticals.
• Expand utilization at Cana Laboratories and U.S. facilities.
• Enhance CosmoFarm's efficiency and reach.
• Maintain strict financial discipline, focusing on cost controls and operating leverage.
• Launch Cloudscreen 2.0 to enhance internal discovery and opportunities for collaborations, licensing, and joint ventures.
• Evaluate strategic options such as a potential spin-off of the R&D division.
• Pursue disciplined acquisitions and alliances to broaden distribution, technology, and branded products.

Key Dates

Recommendation

The filing outlines a clear and ambitious growth strategy backed by significant financial and operational milestones. The $300 million digital asset facility provides substantial capital for growth and diversification, while the expansion of manufacturing in both Europe and the U.S. enhances vertical integration and margin potential. Strong H1 2025 financial performance, including double-digit revenue growth and a 53% increase in gross profit, indicates positive momentum. The CEO's substantial personal investment signals strong insider confidence. The company's focus on AI-driven R&D, global brand expansion, and clear 2027 financial targets (revenue of $155.8M, Adjusted EBITDA of $29.4M, positive operating cash flow) positions it for significant future value creation. While 2024 saw a net loss, it is framed as an investment year, and the subsequent 2025 performance suggests a positive inflection point.

Keywords

Healthcare, Pharmaceuticals, Nutraceuticals, Digital Assets, Manufacturing, AI, Drug Discovery, Global Expansion, NASDAQ:COSM, Sky Premium Life, Cana Laboratories, CosmoFarm, Cloudscreen, Obesity Treatment, Oncology, Generics, Diagnostics, Corporate Treasury